Geographical variation in Plasmodium vivax relapse
暂无分享,去创建一个
David L. Smith | P. Gething | S. Hay | K. Battle | R. Howes | J. Baird | N. Golding | S. Bhatt | T. V. Van Boeckel | J. Messina | G. Shanks | Markku S Karhunen
[1] Leah Blau,et al. Statistical Models In Epidemiology , 2016 .
[2] David L. Smith,et al. Geographical variation in Plasmodium vivax relapse , 2014, Malaria Journal.
[3] S. Krudsood,et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.
[4] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[5] N. White,et al. The activation of vivax malaria hypnozoites by infectious diseases. , 2013, The Lancet. Infectious diseases.
[6] R. Coker,et al. Quantifying Effect of Geographic Location on Epidemiology of Plasmodium vivax Malaria , 2013, Emerging infectious diseases.
[7] Mulyanto,et al. The Evolutionary History of Plasmodium vivax as Inferred from Mitochondrial Genomes: Parasite Genetic Diversity in the Americas , 2013, Molecular biology and evolution.
[8] Susanne A. Fritz,et al. An Update of Wallace’s Zoogeographic Regions of the World , 2013, Science.
[9] M. Galinski,et al. Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. , 2013, Advances in parasitology.
[10] S. Hay,et al. G6PD deficiency: global distribution, genetic variants and primaquine therapy. , 2013, Advances in parasitology.
[11] X. Su,et al. Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico , 2013, Parasites & Vectors.
[12] J. Burrows,et al. The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.
[13] David L. Smith,et al. A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010 , 2012, PLoS neglected tropical diseases.
[14] P. Gething,et al. The global public health significance of Plasmodium vivax. , 2012, Advances in parasitology.
[15] N. White. Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.
[16] David L. Smith,et al. Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax , 2011, Parasites & Vectors.
[17] Caroline W. Kabaria,et al. The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic précis , 2011, Parasites & Vectors.
[18] Teun Bousema,et al. Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.
[19] R. Price,et al. Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] David L. Smith,et al. Erratum: Ranking of elimination feasibility between malaria-endemic countries (Lancet (2010) 376 (1579-1591)) , 2011 .
[21] J. Baird. Eliminating malaria—all of them , 2010, The Lancet.
[22] Andrew J Tatem,et al. Ranking of elimination feasibility between malaria-endemic countries , 2010, The Lancet.
[23] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[24] R. Price,et al. Artemisinin combination therapy for vivax malaria. , 2010, The Lancet. Infectious diseases.
[25] Anand P. Patil,et al. Estimating the Global Clinical Burden of Plasmodium falciparum Malaria in 2007 , 2010, PLoS medicine.
[26] Sue J Lee,et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial , 2010, Malaria Journal.
[27] J. Baird,et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. , 2010, Trends in parasitology.
[28] L. Hedges,et al. The Handbook of Research Synthesis and Meta-Analysis , 2009 .
[29] R. Price,et al. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance , 2009, Current opinion in infectious diseases.
[30] J. Baird,et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. , 2009, The Lancet. Infectious diseases.
[31] Simon I Hay,et al. Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation , 2009, Malaria Journal.
[32] R. Price,et al. Vivax malaria: a major cause of morbidity in early infancy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Bruce Russell,et al. The pathophysiology of vivax malaria. , 2009, Trends in parasitology.
[34] Stephen W. Raudenbush,et al. Analyzing effect sizes: Random-effects models. , 2009 .
[35] R. Price,et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum , 2008, Malaria Journal.
[36] R. Price,et al. Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia , 2008, PLoS medicine.
[37] M. Alpers,et al. Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea , 2008, PLoS medicine.
[38] R. Price,et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] Nicholas J White,et al. Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.
[40] I. Elyazar,et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. , 2007, The American journal of tropical medicine and hygiene.
[41] T. McMahon,et al. Updated world map of the Köppen-Geiger climate classification , 2007 .
[42] R. Price,et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.
[43] A. Omari,et al. Primaquine for preventing relapses in people with Plasmodium vivax malaria. , 2007, The Cochrane database of systematic reviews.
[44] Andrew J Tatem,et al. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project , 2007, Malaria Journal.
[45] J. Carmona-Fonseca,et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. , 2006, The American journal of tropical medicine and hygiene.
[46] H. Dagoro,et al. Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? , 2006, Malaria Journal.
[47] Wolfgang Viechtbauer,et al. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .
[48] A. Das,et al. Plasmodium vivax Malaria , 2005, Emerging infectious diseases.
[49] S. Hoffman,et al. Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] J. Baird,et al. Chloroquine Resistance in Plasmodium vivax , 2004, Antimicrobial Agents and Chemotherapy.
[51] J. Sattabongkot,et al. Plasmodium vivax transmission: chances for control? , 2004, Trends in parasitology.
[52] J. Baird,et al. Can primaquine therapy for vivax malaria be improved? , 2003, Trends in parasitology.
[53] F. McKenzie,et al. PLASMODIUM VIVAX BLOOD-STAGE DYNAMICS , 2002, The Journal of parasitology.
[54] J. Sullivan,et al. EXPERIMENTAL INFECTION OF ANOPHELES FARAUTI WITH DIFFERENT SPECIES OF PLASMODIUM , 2002, The Journal of parasitology.
[55] J. Sachs,et al. The economic and social burden of malaria , 2002, Nature.
[56] G. Powell,et al. Terrestrial Ecoregions of the World: A New Map of Life on Earth , 2001 .
[57] K. Mendis,et al. The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.
[58] N. Gogtay,et al. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. , 1999, Annals of tropical medicine and parasitology.
[59] S. Lal,et al. Epidemiology and control of malaria , 1999, Indian journal of pediatrics.
[60] W. Perea,et al. Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[61] Pandey Kc,et al. Role of An. culicifacies and An. stephensi in malaria transmission in urban Delhi. , 1993 .
[62] S. Subbarao,et al. Role of An. culicifacies and An. stephensi in malaria transmission in urban Delhi. , 1993, Indian journal of malariology.
[63] K Ulm,et al. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR) , 1990, American journal of epidemiology.
[64] K. Rieckmann,et al. PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? , 1989, The Lancet.
[65] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[66] W. Wernsdorfer,et al. Malaria: Principles and Practice of Malariology , 1989 .
[67] Krotoski Wa,et al. The hypnozoite and malarial relapse. , 1989 .
[68] W A Krotoski,et al. The hypnozoite and malarial relapse. , 1989, Progress in clinical parasitology.
[69] W. Wernsdorfer,et al. Malaria parasites of man: life-cycles and morphology (excluding ultrastructure). , 1988 .
[70] S. Looareesuwan,et al. HIGH RATE OF PLASMODIUM VIVAX RELAPSE FOLLOWING TREATMENT OF FALCIPARUM MALARIA IN THAILAND , 1987, The Lancet.
[71] G. R. Coatney. Relapse in malaria--an enigma. , 1976, Journal of Parasitology.
[72] P. G. Shute,et al. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. , 1976, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[73] P. G. Shute,et al. A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. , 1975, Bulletin of the World Health Organization.
[74] W. Collins,et al. Primate malarias. , 1974, Advances in veterinary science and comparative medicine.
[75] A. Gehani,et al. [G6PD deficiency]. , 1974, Xianggang hu li za zhi. The Hong Kong nursing journal.
[76] H. Notopuro,et al. Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.
[77] Rakitzis Et,et al. ENZYME-STRIP ESTIMATION OF BLOOD-GLUCOSE. , 1964 .
[78] D. Mattingly,et al. INTRACRANIAL HYPERTENSION AND STEROIDS. , 1964, Lancet.
[79] J. Beck. A Textbook of Malaria Eradication , 1963 .
[80] C. Winckel. Long latency in Plasmodium vivax infections in a temperate zone. , 1955, Documenta de medicina geographica et tropica.
[81] R. J. Dern,et al. Natural history of Korean vivax malaria after deliberate inoculation of human volunteers. , 1954, Journal of Laboratory and Clinical Medicine.
[82] G. Coatney,et al. Korean vivax malaria. I. Natural history and response to chloroquine. , 1953, The American journal of tropical medicine and hygiene.
[83] A. Di Lorenzo,et al. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. , 1953, The American journal of tropical medicine and hygiene.
[84] G. Coatney,et al. Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria. , 1953, The American journal of tropical medicine and hygiene.
[85] J. Tukey,et al. Transformations Related to the Angular and the Square Root , 1950 .
[86] R. W. Burgess,et al. STUDIES IN HUMAN MALARIAXVIII. THE LIFE PATTERN OF SPOROZOITE-INDUCED ST. ELIZABETH STRAIN VIVAX MALARIA , 1950 .
[87] W. C. Cooper,et al. Studies in human malaria; the protective and therapeutic action of quinacrine against St. Elizabeth strain vivax malaria. , 1949, American journal of hygiene.
[88] R. Berliner,et al. STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. V. THE ANTIMALARIAL ACTIVITY OF QUINACRINE. , 1948, Journal of Clinical Investigation.
[89] Coatney Gr,et al. Recrudescence and relapse in vivax malaria. , 1948 .
[90] D. Earle,et al. Studies on the chemotherapy of the human malarias; the antimalarial activity of quinacrine. , 1948, Journal of Clinical Investigation.
[91] G. Coatney,et al. Recrudescence and relapse in vivax malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.
[92] M. D. Young,et al. Studies in Human Malaria. I. The Protective Action of Sulfadiazine and Sulfapyrazine against Sporozoite-induced Falciparum Malaria. , 1949 .
[93] M. L. Crossley,et al. RECENT ADVANCES IN CHEMOTHERAPY , 1940, Science.
[94] M. Boyd. The Influence of Sporozoite Dosage in Vivax Malaria. , 1940 .
[95] S. Kitchen,et al. On the Infectiousness of Patients infected with Plasmodium vivax and Plasmodium falciparum. , 1937 .
[96] Amico Bigxami. Concerning the Pathogenesis of Relapses in Malarial Fevers. , 2022 .